The above results suggested CLL cells activated by IL-2 and a TLR7-agonist in the presence of ruxolitinib cannot make high amounts of IL-10 due to the absence of an amplifying signal from cytokines including IL-10 but also exhibit signs of increased NFκB-signaling (Figure 3). Here, TLR7 is linked to B-cell chronic lymphocytic leukemia.